Phase I of trastuzumab and imatinib mesylate (Gleevec formerly known as STI-571) in patients with recurrent or metastatic HER-2/Neu expressing cancer.

Trial Profile

Phase I of trastuzumab and imatinib mesylate (Gleevec formerly known as STI-571) in patients with recurrent or metastatic HER-2/Neu expressing cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Feb 2010

At a glance

  • Drugs Imatinib (Primary) ; Trastuzumab
  • Indications Cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Feb 2010 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
    • 16 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Sep 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top